Wall Street promptly began trying to weigh the compound’s marketplace odds after Merck & Co. Inc. detailed positive data from the phase IIb/III trial known as MK-1654-004 with clesrovimab, an ...

Merck reported positive results for its experimental treatment designed to protect infants from RSV. The mid to late-stage ...

We recently published a list of 10 Best Medical Stocks to Buy Now. In this article, we are going to take a look at where ...

Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some ...

Drug makers Exelixis, Inc. (EXEL) and Merck & Co Inc.(MRK) announced Monday that they have entered into a clinical development ...

Each year, Medical Design & Outsourcing collects thousands of data points to rank and analyze the largest medical device companies in the world, including publicly traded companies and privately held ...

Merck & Co. hopes a new positive trial readout can return Keytruda to glory in head and neck cancer. | Merck & Co. hopes a ...

Merck's history dates back to the late 1800s ... Then, Summit Therapeutics goes after many other indications for this medicine. It could be a pipeline in a drug as it is being investigated ...

People might refer to conventional or traditional medicine as “allopathic” medicine. In allopathic medicine, healthcare professionals use a range of treatments to treat infection, illness ...

Merck's Keytruda could face competition from a newer medicine. The company's crown jewel will also lose patent exclusivity in a few years. Merck should have the means to get around these headwinds.

The cancer drug has been Merck's top-selling medicine and its biggest growth driver -- by a mile. And last year, it became the best-selling drug worldwide, taking over from the immunology ...